GlassScriptPhysician profile
Mahmood Ali
NPI 1356359129
$13,596.36
in general payments reported to CMS, 2019-2025
43 companies · $1,826 in 2025
The $1,826 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,339 · 2020: $1,839 · 2021: $1,612 · 2022: $2,271 · 2023: $1,892 · 2024: $1,818 · 2025: $1,826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,469 · Education: $67.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,468.58 |
| Education | $67.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,359.18 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $2,058.48 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Philips North America LLC | $1,853.39 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Actelion Pharmaceuticals US, INC. | $1,193.77 | 2019-2025 | Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $782.11 | 2019-2025 | Ofev, Stiolto Respimat, Jascayd |
| Regeneron Healthcare Solutions, INC. | $763.93 | 2019-2025 | Dupixent |
| Genzyme Corporation | $506.87 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $390.05 | 2019-2025 | |
| Mylan Specialty L.P. | $371.94 | 2019-2024 | Yupelri |
| Sunovion Pharmaceuticals INC. | $358.29 | 2019-2020 | |
| Harmony Biosciences LLC | $284.18 | 2020-2022 | |
| Insmed, INC. | $261.61 | 2019-2025 | Arikayce |
| Genentech USA, INC. | $236.42 | 2019-2023 | Xolair |
| Gilead Sciences, INC. | $226.36 | 2020-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $226.25 | 2019-2024 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $208.10 | 2023-2025 | Tezspire |
| Grifols USA, LLC | $201.72 | 2019-2023 | Prolastin-C Liquid |
| Electromed, INC. | $170.43 | 2019-2025 | Smartvest |
| Verona Pharma, INC. | $112.50 | 2025 | Ohtuvayre |
| Jazz Pharmaceuticals INC. | $104.94 | 2019-2025 | |
| United Therapeutics Corporation | $104.31 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $94.84 | 2021-2023 | Acthar |
| Pulmonx Corporation | $88.76 | 2024-2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Takeda Pharmaceuticals U.S.A., INC. | $81.36 | 2022-2024 | Glassia |
| Advanced Respiratory, INC | $68.60 | 2020-2021 | |
| Inogen, INC. | $67.67 | 2021-2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Baxter Healthcare | $62.32 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Shire North American Group INC | $53.66 | 2019 | |
| Merck Sharp & Dohme LLC | $52.79 | 2022 | |
| Covis Pharma Gmbh | $31.14 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $30.27 | 2019-2020 | |
| Circassia INC. | $26.85 | 2019-2020 | |
| Vapotherm INC | $23.50 | 2023 | Vapotherm |
| Resmed Corp | $20.75 | 2025 | |
| Pfizer INC. | $20.48 | 2024 | |
| Abbvie INC. | $19.34 | 2024 | |
| Phadia US INC. | $18.62 | 2023 | Immunocap |
| Paratek Pharmaceuticals, INC. | $17.44 | 2024 | Nuzyra |
| Allergan, INC. | $15.48 | 2019 | |
| Viatris Specialty LLC | $13.98 | 2025 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $13.68 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mahmood Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.